STOCK TITAN

Evolus Inc - EOLS STOCK NEWS

Welcome to our dedicated news page for Evolus (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evolus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evolus's position in the market.

Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) announced Nareg Sagherian as Vice President, Head of Global Investor Relations and Corporate Communications. Nareg brings extensive experience in capital markets, investor relations, corporate communications, and public policy from firms including FTI Consulting, Biotechnology Innovation Organization, and Booz Allen Hamilton. He will report to Sandra Beaver, Chief Financial Officer of Evolus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
management
-
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) has entered into a distributor agreement with Symatese to expand its dermal filler footprint beyond the U.S. to include the United Kingdom and Europe. European regulatory approvals are anticipated in the second half of 2024, with commercialization under the brand name Estyme® fillers in 2025. This agreement doubles the company's total addressable international market to $1.8 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
none
-
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) granted 28,328 restricted stock units (RSUs) to 7 non-executive employees under the 2023 Inducement Incentive Plan, with vesting over 4 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) reported the grant of non-qualified stock options and restricted stock units (RSUs) to newly hired non-executive employees. The awards were approved under the 2023 Inducement Incentive Plan, with vesting schedules and exercise prices specified. The grants were made as inducements for new employees entering into employment with Evolus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) reports record quarterly net revenue of $50 million for Q3 2023, a 48% increase from Q3 2022, and raises full-year 2023 net revenue guidance. Operating use of cash in Q3 was $0.9 million, with a focus on achieving profitability. Positive Phase II data for 'Extra-Strength' 40U Formulation of Jeuveau® presented at 2023 American Society of Dermatologic Surgery Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.17%
Tags
earnings clinical trial
-
Rhea-AI Summary
Evolus, Inc. announced results from a Phase 2 clinical study on the 'extra-strength' 40U dose of Jeuveau, demonstrating a duration of 26 weeks or 6 months. The study showed that the 40U formulation had similar safety profiles to lower dose arms. The results were presented at the 2023 ASDS Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
clinical trial
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) will present at the Stifel 2023 Healthcare Conference on November 15, 2023, and at the 6th Annual Evercore ISI HealthCONx Conference on November 28, 2023. Audio webcasts of the events will be available on Evolus' website, with replays available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
conferences
-
Rhea-AI Summary
Evolus, Inc. will report its Q3 2023 financial results and provide a business update on November 7, 2023. A conference call and webcast will be held to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
conferences earnings
-
Rhea-AI Summary
Evolus to present final results from Phase 2 study at 2023 ASDS Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
clinical trial
Rhea-AI Summary
Evolus, Inc. grants stock options and restricted stock units to new employees under the 2023 Inducement Incentive Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Evolus Inc

Nasdaq:EOLS

EOLS Rankings

EOLS Stock Data

860.97M
38.81M
13.06%
76.87%
8.58%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Newport Beach

About EOLS

evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.